Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients
A completed study evaluating deep learning-based optical coherence tomography and OCT angiography imaging in patients with Waldenström macro…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia [Phase 3]
A Phase 3 study in Waldenström's macroglobulinemia completed evaluating the first-line DRC regimen with or without bortezomib, reporting eff…
-
CLINICAL_TRIALS research · 2024-05-10Clinical Trial Update: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia [Phase 2, Phase 3]
A Phase 2/Phase 3 randomized trial at University College London compares Rituxan (rituximab) plus Ibrutinib versus Dexamethasone, Rituxan, a…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia [Phase 1]
Phase 1 study evaluating the combination of ulocuplumab and ibrutinib in patients with mutated CXCR4 Waldenström's macroglobulinemia was ter…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Ibrutinib + Venetoclax in Untreated WM [Phase 2]
A Phase 2 trial evaluating the combination of ibrutinib and venetoclax in patients with untreated Waldenström macroglobulinemia, with result…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia [Phase 2]
Phase 2 trial update for ICP-022 in recurrent or refractory Waldenstrom macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer [Phase 2]
Phase 2 study evaluating a conditioning regimen of fludarabine phosphate, cyclophosphamide, and total body irradiation followed by donor ste…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Dasatinib In Waldenström Macroglobulinemia [Phase 1]
Phase 1 trial of dasatinib in Waldenström macroglobulinemia was terminated; results posted in 2024.
-
FDA approval · 2024-02-22FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia [Phase 2]
Phase 2 clinical trial investigating daratumumab plus ibrutinib in Waldenström's macroglobulinemia; study status terminated with posted resu…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia [Phase 2]
A Phase 2 trial assessing zanubrutinib in combination with bendamustine/rituximab for newly diagnosed Waldenström's macroglobulinemia.
-
CLINICAL_TRIALS trial_result · 2023-08-29Clinical Trial Update: Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial assessing the efficacy of idelalisib plus obinutuzumab in relapsed/refractory Waldenström's macroglobulinemia has bee…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) [Phase 3]
Phase 3 trial comparing zanubrutinib (BGB-3111) with ibrutinib in Waldenström's macroglobulinemia. The study is completed and results have b…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]
Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-01Clinical Trial Update: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) [Phase 2]
Phase 2 study in Japan evaluating the combination of ibrutinib with rituximab in Waldenström macroglobulinemia has completed with results po…
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approves a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC. The document indicates FDA approval of the…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating the combination of bortezomib and rituximab in Waldenström's macroglobulinemia; the study is active but no…
-
CLINICAL_TRIALS trial_result · 2022-04-13Clinical Trial Update: A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 [Phase 2]
Phase II study of carfilzomib in relapsed Waldenström's macroglobulinemia has completed, with results posted in April 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) [Phase 2]
Phase 2 study of the BTK inhibitor BGB-3111 (zanubrutinib) in Chinese patients with relapsed/refractory Waldenström's macroglobulinemia has …